首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   17065篇
  免费   1336篇
  国内免费   47篇
耳鼻咽喉   137篇
儿科学   386篇
妇产科学   415篇
基础医学   2821篇
口腔科学   288篇
临床医学   1740篇
内科学   3672篇
皮肤病学   295篇
神经病学   1584篇
特种医学   547篇
外国民族医学   4篇
外科学   2393篇
综合类   178篇
一般理论   4篇
预防医学   1329篇
眼科学   267篇
药学   1054篇
中国医学   9篇
肿瘤学   1325篇
  2021年   220篇
  2020年   163篇
  2019年   261篇
  2018年   302篇
  2017年   212篇
  2016年   223篇
  2015年   293篇
  2014年   398篇
  2013年   563篇
  2012年   806篇
  2011年   805篇
  2010年   432篇
  2009年   476篇
  2008年   778篇
  2007年   757篇
  2006年   790篇
  2005年   696篇
  2004年   704篇
  2003年   696篇
  2002年   672篇
  2001年   561篇
  2000年   604篇
  1999年   473篇
  1998年   182篇
  1997年   168篇
  1996年   152篇
  1995年   129篇
  1994年   147篇
  1993年   112篇
  1992年   374篇
  1991年   346篇
  1990年   368篇
  1989年   329篇
  1988年   336篇
  1987年   313篇
  1986年   323篇
  1985年   286篇
  1984年   217篇
  1983年   174篇
  1981年   109篇
  1979年   163篇
  1978年   161篇
  1977年   138篇
  1976年   109篇
  1975年   156篇
  1974年   181篇
  1973年   135篇
  1972年   137篇
  1971年   141篇
  1970年   121篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Introduction: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype associated with an increased risk of recurrence and cancer-related death. Unlike hormone receptor-positive or HER2-positive breast cancers, there are limited targeted therapies available to treat TNBC and cytotoxic chemotherapy remains the mainstay of treatment. Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate targeting Trop-2 expressing cells and selectively delivering SN-38, an active metabolite of irinotecan.

Areas covered: This review covers the mechanism of action, safety and efficacy of sacituzumab govitecan in patients with previously treated, metastatic TNBC. Additionally, efficacy data in other epithelial malignancies is included based on a PubMed search for ‘sacituzumab govitecan’ and ‘clinical trial’.

Expert opinion: Sacituzumab govitecan has promising anti-cancer activity in patients with metastatic TNBC previously treated with at least two prior lines of systemic therapy based on a single arm Phase I/II clinical trial. A confirmatory Phase III randomized clinical trial is ongoing. Sacituzumab govitecan has a manageable side effect profile, with the most common adverse events being nausea, neutropenia, and diarrhea. The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer.  相似文献   

2.
3.
4.
5.
6.
7.
8.
This paper presents 14 examples of a distinctive cardiovascular lesion. The patients' ages ranged from 5 to 76 years (mean, 51 years). There were seven male patients and seven female patients. All of the lesions were small and represented incidental surgical findings. Ten were attached to the endocardium, three were free-floating in the pericardial cavity, and one was inside a dissecting aneurysm of the ascending aorta. Microscopically, the lesions were enclosed in a fibrinous network and composed of a solid proliferation of round to polygonal cells with centrally located nuclei. Immunohistochemically, the cells were negative for FVIII-related antigen and lysozyme, but they stained positively for keratin, especially when clustered in small micropapillary or tubule-like formations. The nature and pathogenesis of these lesions are uncertain. Their location and some of their microscopic features originally suggested a relationship with the entity described as histiocytoid (epithelioid) hemangioma. However, their intense immunoreactivity for keratin, occasional presentation in the pericardial sac, and marked morphologic similarities with nodular mesothelial hyperplasia as sometimes seen in hernia sacs point toward the alternative possibility of a reactive mesothelial nature. A possible pathogenetic mechanism for the endocardial cases is ingrowth of pericardial mesothelial cells along a perforation tract that may have developed at the time of a cardiac catheterization. There were no recurrences or metastases in any of the cases.  相似文献   
9.
BookReviews     
Annals of Vascular Surgery -  相似文献   
10.
In the present experiments we have investigated the influence of wall shear rate and axial position on platelet and fibrin deposition which results when flowing human non-anticoagulated blood is exposed to either non-procoagulant fibrillar collagen (human type III) or procoagulant subendothelium (rabbit aorta). Platelet adhesion, thrombus volume and fibrin deposition were morphometrically evaluated at axial positions of 1 and 13 mm following perfusions for 5 min at shear rates of 100, 650 and 2,600 s-1. An axially-dependent decrease of platelet adhesion (34-57%, p less than 0.01-0.05) and thrombus volume (57-80%, p less than 0.05) was observed on collagen at all shear rates. On subendothelium, an axially-dependent decrease was observed for platelet adhesion only at 100 s-1 (29%; p less than 0.01) and for thrombus volume at shear rates of 650 s-1 and above (49-58%, p less than 0.01). Deposition of fibrin on subendothelium was axially decreased (16-42%, p less than 0.05) at all shear rates, while no significant axial differences were seen on collagen. However, substantially more fibrin was deposited on the subendothelium (p less than 0.05), and the upstream platelet adhesion and thrombus volume were lower than on collagen (p less than 0.05) at 100 s-1 and 650 s-1. The axially-dependent phenomena on the two surfaces are consistent with the concept of rapid-growing upstream thrombi which deplete the blood layer streaming adjacent ot the surface of platelets, leading to decreased platelet deposition further downstream.(ABSTRACT TRUNCATED AT 250 WORDS)  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号